awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35230041-247D96E5-1FB0-49F9-BC2F-FED89A972F05
Q35230041-247D96E5-1FB0-49F9-BC2F-FED89A972F05
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35230041-247D96E5-1FB0-49F9-BC2F-FED89A972F05
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
P2860
Q35230041-247D96E5-1FB0-49F9-BC2F-FED89A972F05
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35230041-247D96E5-1FB0-49F9-BC2F-FED89A972F05
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ac3d01ea6fef097c3f9a0c67629526e4419d21c2
P2860
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.